Extracellular vesicles and PD-L1 suppress macrophages, inducing therapy resistance in TP53-deficient B-cell malignancies.

Autor:	Izquierdo E; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Vorholt D; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Blakemore S; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Sackey B; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Nolte JL; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Barbarino V; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Schmitz J; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Nickel N; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Bachurski D; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Lobastova L; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Nikolic M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany., Michalik M; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Brinker R; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Merkel O; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Franitza M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany., Georgomanolis T; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.; West German Genome Center (WGGC), Cologne, Germany., Neuhaus R; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Koch M; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Nasada N; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Knittel G; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Chapuy B; Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Charité - University Medical Center Berlin, corporate member of Free University Berlin and Humboldt-University Berlin, Berlin, Germany., Ludwig N; Institute for Human Genetics, University of Saarland, Homburg/Saar, Germany., Meese E; Institute for Human Genetics, University of Saarland, Homburg/Saar, Germany., Frenzel L; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Reinhardt HC; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and.; Clinic for Hematology and Stem Cell Transplantation, University Hospital Essen, University Duisburg-Essen, Essen, Germany; and., Peifer M; Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany., Rebollido-Rios R; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Bruns H; Department of Internal Medicine, University of Erlangen, Erlangen, Germany., Krüger M; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Hallek M; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and., Pallasch CP; Department I of Internal Medicine, Center for Integrated Oncology (CIO) Köln-Bonn.; Cologne Excellence Cluster for Cellular Stress Responses in Ageing-Associated Diseases (CECAD), and.
Jazyk:	angličtina
Zdroj:	Blood [Blood] 2022 Jun 23; Vol. 139 (25), pp. 3617-3629.
DOI:	10.1182/blood.2021014007
Abstrakt:	Genetic alterations in the DNA damage response (DDR) pathway are a frequent mechanism of resistance to chemoimmunotherapy (CIT) in B-cell malignancies. We have previously shown that the synergy of CIT relies on secretory crosstalk elicited by chemotherapy between the tumor cells and macrophages. Here, we show that loss of multiple different members of the DDR pathway inhibits macrophage phagocytic capacity in vitro and in vivo. Particularly, loss of TP53 led to decreased phagocytic capacity ex vivo across multiple B-cell malignancies. We demonstrate via in vivo cyclophosphamide treatment using the Eμ-TCL1 mouse model that loss of macrophage phagocytic capacity in Tp53-deleted leukemia is driven by a significant downregulation of a phagocytic transcriptomic signature using small conditional RNA sequencing. By analyzing the tumor B-cell proteome, we identified a TP53-specific upregulation of proteins associated with extracellular vesicles (EVs). We abrogated EV biogenesis in tumor B-cells via clustered regularly interspaced short palindromic repeats (CRISPR)-knockout (KO) of RAB27A and confirmed that the EVs from TP53-deleted lymphoma cells were responsible for the reduced phagocytic capacity and the in vivo CIT resistance. Furthermore, we observed that TP53 loss led to an upregulation of both PD-L1 cell surface expression and secretion of EVs by lymphoma cells. Disruption of EV bound PD-L1 by anti-PD-L1 antibodies or PD-L1 CRISPR-KO improved macrophage phagocytic capacity and in vivo therapy response. Thus, we demonstrate enhanced EV release and increased PD-L1 expression in TP53-deficient B-cell lymphomas as novel mechanisms of macrophage function alteration in CIT resistance. This study indicates the use of checkpoint inhibition in the combination treatment of B-cell malignancies with TP53 loss. (© 2022 by The American Society of Hematology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu